Next Article in Journal
Differences in the Effects of EGCG on Chromosomal Stability and Cell Growth between Normal and Colon Cancer Cells
Previous Article in Journal
ω-Methylsulfanylalkyl Glucosinolates: A General Synthetic Pathway
Review

Regulating Cdc42 and Its Signaling Pathways in Cancer: Small Molecules and MicroRNA as New Treatment Candidates

by 1,2,†, 1,2,†, 1,2, 1,2, 1,2, 1,2,* and 1,2,*
1
Department of Pathophysiology, Medical College, Nanchang University, 461 Bayi Road, Nanchang 330006, China
2
Jiangxi Province Key Laboratory of Tumor Pathogenesis and Molecular Pathology, 461 Bayi Road, Nanchang 330006, China
*
Authors to whom correspondence should be addressed.
These authors contributed equally to this work.
Received: 27 February 2018 / Revised: 19 March 2018 / Accepted: 24 March 2018 / Published: 29 March 2018
(This article belongs to the Section Medicinal Chemistry)
Despite great improvements in the diagnosis and treatment of neoplasms, metastatic disease is still the leading cause of death in cancer patients, with mortality rates still rising. Given this background, new ways to treat cancer will be important for development of improved cancer control strategies. Cdc42 is a member of the Rho GTPase family and plays an important role in cell-to-cell adhesion, formation of cytoskeletal structures, and cell cycle regulation. It thus influences cellular proliferation, transformation, and homeostasis, as well as the cellular migration and invasion processes underlying tumor formation. Cdc42 acts as a collection point for signal transduction and regulates multiple signaling pathways. Moreover, recent studies show that in most human cancers Cdc42 is abnormally expressed and promoting neoplastic growth and metastasis. Regarding possible new treatments for cancer, miRNA and small molecules targeting Cdc42 and related pathways have been recently found to be effective on cancer. In this review, we analyze the newly recognized regulation mechanisms for Cdc42 and Cdc42-related signal pathways, and particularly new treatments using small molecules and miRNAs to inhibit the abnormal overexpression of Cdc42 that may slow down the metastasis process, improve cancer therapy and lead to novel strategies for development of antineoplastic drugs. View Full-Text
Keywords: Cdc42; Cdc42-related signaling pathways; small molecules; miRNAs; cancer therapy Cdc42; Cdc42-related signaling pathways; small molecules; miRNAs; cancer therapy
Show Figures

Figure 1

MDPI and ACS Style

Xiao, X.-H.; Lv, L.-C.; Duan, J.; Wu, Y.-M.; He, S.-J.; Hu, Z.-Z.; Xiong, L.-X. Regulating Cdc42 and Its Signaling Pathways in Cancer: Small Molecules and MicroRNA as New Treatment Candidates. Molecules 2018, 23, 787. https://0-doi-org.brum.beds.ac.uk/10.3390/molecules23040787

AMA Style

Xiao X-H, Lv L-C, Duan J, Wu Y-M, He S-J, Hu Z-Z, Xiong L-X. Regulating Cdc42 and Its Signaling Pathways in Cancer: Small Molecules and MicroRNA as New Treatment Candidates. Molecules. 2018; 23(4):787. https://0-doi-org.brum.beds.ac.uk/10.3390/molecules23040787

Chicago/Turabian Style

Xiao, Xing-Hua, Lin-Chen Lv, Jing Duan, Ye-Meng Wu, Shu-Jin He, Zhen-Zhen Hu, and Li-Xia Xiong. 2018. "Regulating Cdc42 and Its Signaling Pathways in Cancer: Small Molecules and MicroRNA as New Treatment Candidates" Molecules 23, no. 4: 787. https://0-doi-org.brum.beds.ac.uk/10.3390/molecules23040787

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop